欧洲每年超过5000例转移性黑色素瘤患者无法获得推荐的一线创新治疗
该研究通过覆盖30个欧洲国家的网络调查,分析2015年5月1日至2016年5月1日转移性黑色素瘤创新治疗的可及性。结果显示,推荐的一线BRAF抑制剂联合MEK抑制剂在9/30(30%)国家注册并全额报销,抗PD1免疫治疗在14/30(47%)国家注册并全额报销;估计欧洲每年19600例患者接受治疗,其中5238例(27%)无法获得推荐一线治疗。
要点
- 推荐的一线BRAF抑制剂联合MEK抑制剂在9/30(30%)国家注册并全额报销。
- 一线抗PD1免疫治疗在14/30(47%)国家注册并全额报销。
- 估计欧洲每年5238例(27%)转移性黑色素瘤患者无法获得推荐一线治疗。
核心结论
- 欧洲转移性黑色素瘤治疗存在巨大差异,亟需提高国家及欧洲政策制定者、肿瘤学会、患者协会和制药行业的意识。
研究设计与样本
- 网络在线调查,覆盖30个欧洲国家,询问2015年5月1日至2016年5月1日期间的治疗方案、转移性黑色素瘤患者数量、创新药物的注册与报销情况(数据更新至2016年10月1日)、治疗患者百分比以及临床研究和同情用药项目的可及性。
主要发现
- 推荐的一线BRAF抑制剂联合MEK抑制剂在9/30(30%)国家注册并全额报销,在13/30(43%)(均为东欧国家)未报销。
- 一线抗PD1抗体免疫治疗在14/30(47%)国家注册并全额报销,在13/30(43%)(均为东欧国家)未报销。
- 估计欧洲有19600例转移性黑色素瘤患者接受治疗,其中5238例(27%)无法获得推荐一线治疗。
- 人类发展指数(HDI,UNDP 2015年报告)与接受创新药物治疗的患者百分比及报销药物数量显著相关(r=0.662;p<0.001)。
- 人均卫生支出与接受创新药物治疗的患者百分比及报销药物数量显著相关(r=0.695;p<0.001)。
关键数值与推荐
- 推荐的一线BRAF抑制剂联合MEK抑制剂在9/30(30%)国家注册并全额报销,13/30(43%)国家未报销。
- 一线抗PD1抗体免疫治疗在14/30(47%)国家注册并全额报销,13/30(43%)国家未报销。
- 欧洲估计19600例转移性黑色素瘤患者接受治疗,5238例(27%)无法获得推荐一线治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). MATERIALS AND METHODS: Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes. RESULTS: The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r = 0.662; p < 0.001), health expenditure per capita (r = 0.695; p < 0.001) and the Mackenbach score of health policy performance (r = 0.765; p < 0.001) with the percentage of patients treated with innovative medicines and a number of reimbursed medicines. CONCLUSIONS: Great discrepancy exists in metastatic melanoma treatment across Europe. It is crucial to increase the awareness of national and European policymakers, oncological societies, melanoma patients' associations and pharma industry.
引用
- Kandolf Sekulovic L, Peris K, Hauschild A, et al. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. Eur J Cancer. 2017. PMID: 28264791. doi:10.1016/j.ejca.2017.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。